Wednesday, 1 April 2026

The billion-year reign of fungi that predated plants and made Earth livable

Image designed by Tim Sandle
 

Fungi may have shaped Earth’s landscapes long before plants appeared. By combining rare gene transfers with fossil evidence, researchers have traced fungal origins back nearly a billion years earlier than expected. These ancient fungi may have partnered with algae, recycling nutrients, breaking down rock, and creating primitive soils. Far from being silent background players, fungi were ecosystem engineers that prepared Earth’s surface for plants, fundamentally altering the course of life’s history. 

New research from Okinawa Institute of Science and Technology.

Complex multicellular life -- organisms made of many cooperating cells with specialized jobs -- evolved independently in five major groups: animals, land plants, fungi, red algae, and brown algae. On a planet once dominated by single-celled organisms, a revolutionary change occurred not once, but at least five separate times: the evolution of complex multicellular life. Understanding when these groups emerged is fundamental to piecing together the history of life on Earth."

Emergence here was not simply a matter of cells clumping together; it was the dawn of organisms, where cells took on specialized jobs and were organized into distinct tissues and organs, much like in our own bodies. This evolutionary leap required sophisticated new tools, including highly developed mechanisms for cells to adhere to one another and intricate systems for them to communicate across the organism, and arose independently in each of the five major groups.

The difficulties of dating evolutionary divergence

For most of these groups, the fossil record acts as a geological calendar, providing anchor points in deep time. For example, red algae show up possibly as early as about 1.6 billion years ago (in candidate seaweed-like fossils from India); animals appear by around 600 million years ago (Ediacaran fossils such as the quilted pancake like Dickinsonia); land plants take root roughly 470 million years ago (tiny fossil spores); and brown algae (kelp-like forms) diversified tens to hundreds of millions of years later still. Based on this evidence, a chronological picture of life's complexity emerges.

There is, however, a notable exception to this fossil-based timeline: fungi. The fungal kingdom has long been an enigma for paleontologists. Their typically soft, filamentous bodies mean they rarely fossilize well. Furthermore, unlike animals or plants, which appear to have a single origin of complex multicellularity, fungi evolved this trait multiple times from diverse unicellular ancestors, making it difficult to pinpoint a single origin event in the sparse fossil record.

Reading the genetic clock

To overcome the gaps in the fungal fossil record, scientists use a "molecular clock." The concept is that genetic mutations accumulate in an organism's DNA at a relatively steady rate over generations, like the ticking of a clock. By comparing the number of genetic differences between two species, researchers can estimate how long ago they diverged from a common ancestor.

However, a molecular clock is uncalibrated; it can reveal relative time but not absolute years. To set the clock, scientists need to calibrate it with "anchor points" from the fossil record. Given the scarcity of fungal fossils, this has always been a major challenge. The OIST-led team addressed this by incorporating a novel source of information: rare gene "swaps" between different fungal lineages, a process known as horizontal gene transfer (HGT).

While genes are normally passed down "vertically" from parent to child, HGT is like a gene jumping "sideways" from one species to another. These events provide powerful temporal clues," he says. "If a gene from lineage A is found to have jumped into lineage B, it establishes a clear rule: the ancestors of lineage A must be older than the descendants of lineage B.

By identifying 17 such transfers, the team established a series of "older than/younger than" relationships that, alongside fossil records, helped to tighten and constrain the fungal timeline.

A new history for an ancient kingdom

The analysis suggests a common ancestor of living fungi dating to roughly 1.4-0.9 billion years ago -- well before land plants. That timing supports a long prelude of fungi-algae interactions that helped set the stage for life on land.

Fungi run ecosystems -- recycling nutrients, partnering with other organisms, and sometimes causing disease. Pinning down their timeline shows fungi were diversifying long before plants, consistent with early partnerships with algae that likely helped pave the way for terrestrial ecosystems.

This revised timeline fundamentally reframes the story of life's colonization of land. It suggests that for hundreds of millions of years before the first true plants took root, fungi were already present, likely interacting with algae in microbial communities. This long, preparatory phase may have been essential for making Earth's continents habitable. By breaking down rock and cycling nutrients, these ancient fungi could have been the first true ecosystem engineers, creating the first primitive soils and fundamentally altering the terrestrial environment. In this new view, plants did not colonize a barren wasteland, but rather a world that had been prepared for them over eons by the ancient and persistent activity of the fungal kingdom.

The research paper reference is:

Lénárd L. Szánthó, Zsolt Merényi, Philip Donoghue, Toni Gabaldón, László G. Nagy, Gergely J. Szöllősi, Eduard Ocaña-Pallarès. A timetree of Fungi dated with fossils and horizontal gene transfers. Nature Ecology, 2025; DOI: 10.1038/s41559-025-02851-z 

 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Sunday, 29 March 2026

Understanding cleanroom changing room microorganisms


 

Changing rooms act as critical control points within pharmaceutical manufacturing facilities, functioning as microbial airlocks that limit personnel‑borne contamination entering classified processing areas. This study presents a five‑year comparative analysis (2022–2025) of microorganisms recovered from changing rooms and adjacent corridors, spanning cleanroom Grades D, C, and B. 

 

Environmental monitoring data—comprising surface contact plates, settle plates, and active air samples—were analysed and microbial profiles were evaluated. Across all areas, Gram‑positive cocci dominated, especially Micrococcus, Kocuria, and coagulase‑negative Staphylococcus, consistent with human skin flora. Grade D changing rooms showed the highest overall bioburden and organism diversity. 

 

Progressive reductions in microbial burden were observed as personnel transitioned through Grade C into Grade B areas. However, opportunities for improvement in gowning, cleaning, and moisture control were identified. This study provides a comprehensive dataset relating to pharmaceutical changing‑room microbiota and offers a reproducible framework for microbial profiling, trending, and benchmarking across cleanroom facilities.


To access, see:  https://www.ejpps.online/post/comparative-analysis-of-pharmaceutical-facility-changing-room-microbiota 

 

 Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 23 March 2026

Regulatory updates

 


The US Food and Drug Administration (FDA) has issued a draft guidance entitled ‘Computer Software Assurance for Production and Quality Management System Software’. Aimed at medical device manufacturers - check this out and other recent regulatory updates: https://www.rssl.com/insights/life-science-pharmaceuticals/issue-42-pharmaceutical-regulatory-roundup/ 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Saturday, 21 March 2026

Pharmaceutical Resources


 See what Merck has to offer in terms of knowledge and resources, here.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Depyrogenation studies



Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 16 March 2026

Obesity : The Microbiome at the Intersection of Nutrition and Pharma

With more than one billion people living with obesity worldwide—and its economic burden projected to reach $4.32 trillion annually by 2035—obesity remains one of the most pressing global health challenges of the 21st century. While GLP-1–based pharmacotherapies dominate headlines, Seventure Partners—a pioneering venture capital firm specializing in health, nutrition, and microbiome innovation through its dedicated Health for Life Capital funds—is releasing a scientific report that synthesizes global advances in gut microbiome research in obesity and metabolic health, highlighting its potential to serve as a foundation for sustainable, personalized therapeutic strategies that complement and extend conventional drug-based treatments.








A Global Health and Economic Crisis









According to the World Health Organization, 2.5 billion adults were overweight in 2022, including 890 million living with obesity. The World Obesity Atlas 2025 reports that this number has now surpassed one billion. If current trends continue, the WHO projects that 60% of adults will be affected by 2050. The World Obesity Federation estimates that the economic impact of overweight and obesity—including healthcare costs, lost productivity, and premature mortality—will reach $4.32 trillion annually by 2035, equivalent to nearly 3% of global GDP, comparable to the economic impact of COVID-19 in 2020.

 

In this context, GLP-1 (glucagon-like peptide-1) agonists have been hailed as a major breakthrough. The global market for these treatments is expected to reach $105 billion by 2030. However, this therapeutic class, as promising as it may be, also presents certain limitations that the scientific community is documenting with increasing precision.









The Limitations of Exclusively Drug based Approaches


















The Seventure Partners report highlights several unmet needs with current GLP-1 treatments. Clinical studies reveal that fewer than 50% of patients continue their treatment beyond 12 weeks, raising the critical question of result durability. Weight loss effects remain contingent on continuous medication use.

 

Furthermore, these therapies profoundly alter the intestinal ecosystem. GLP-1 agonists change how food transits through the gut and its fermentation patterns, which can disrupt microbiome composition. Other documented effects include loss of muscle mass (not just fat mass), frequent gastrointestinal disorders, and nutritional deficiencies linked to reduced appetite.









"These findings do not call into question the proven benefits of GLP-1s, but they underscore the need for complementary and supplementary approaches to ensure healthy and sustainable weight loss over the long term," the report states.









The Microbiome: An Underutilized Physiological Lever









This is precisely where the gut microbiome offers major opportunities. GLP-1 is not just a pharmaceutical molecule—it is a hormone naturally produced by L-cells in the intestine. And this production is directly modulated by the microbiome.

 

Recent scientific research demonstrates that gut microbiome metabolites—particularly short-chain fatty acids (SCFAs)—naturally stimulate GLP-1 secretion. In other words, a healthy microbiome can activate the same metabolic pathways as medications, through physiological mechanisms.

 

The Seventure Partners report thus identifies the microbiome as a cornerstone of holistic, sustainable therapeutic strategies guided by precision medicine. This approach does not aim to replace existing treatments but to complement them and optimize their long-term effectiveness.









A Rapidly Maturing Market









This convergence of microbiome and metabolism is opening a high-growth market segment. According to analyses by ResearchAndMarkets and Global Industry Analysts, the global microbiome therapeutics market is expected to grow from $1.4 billion in 2024 to $21.5 billion by 2030, representing annual growth of nearly 57%. The obesity segment shows one of the strongest dynamics with a CAGR of 56.8%, alongside opportunities in oncology, chronic and age-related diseases, and gut-brain axis applications (neurodegenerative diseases, mental health, etc.).

 

For comparison, the GLP-1 agonist market is expected to reach $105 billion by 2030 (Morgan Stanley). The 1-to-5 ratio between these two markets illustrates both the maturity of pharmacological approaches and the significant catch-up potential of microbiome-based solutions.

 

Europe shows annual growth of 35.4% in this segment (Grand View Research), driven notably by public-private partnerships and the European Commission's 2025 Biotechnology Roadmap, which prioritizes microbial therapeutics for health and sustainability.









A Broad Range of Therapeutic Innovations









Isabelle de Cremoux's analysis maps the various product categories under development in this field: fecal microbiota transplantation (FMT), Microbiome Restoration Therapy (MRT), live biotherapeutic products (LBPs), next-generation probiotics, prebiotics, postbiotics, and functional dietary fibers. These innovations follow distinct regulatory pathways and offer complementary mechanisms of action.

 

A key finding emerges from the report: the need for personalized approaches. The variability in individual responses to microbiome-based treatments requires consideration of each patient's baseline microbiome composition and functions. This heralds the advent of precision medicine applied to obesity.









Research Priorities to Be Strengthened









The report also identifies priority research areas to accelerate the clinical translation of these approaches: filling remaining mechanistic gaps, prioritizing randomized clinical trials in humans over animal experimentation, and standardizing methodologies for microbiome data collection and analysis.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

High-Functioning Depression: Signs People Miss & How to Get Help

Image by Tim Sandle 

When most people picture depression, they imagine someone who can’t get out of bed, cries often, or withdraws completely from life.

But depression doesn’t always look like that.

Some people wake up early, go to work, meet deadlines, take care of their families, smile in meetings — and quietly struggle the entire time.

This is often referred to as high-functioning depression.

Because it hides behind productivity and responsibility, it frequently goes unnoticed — by friends, coworkers, and even the person experiencing it.

Understanding the signs can make the difference between silent suffering and meaningful support.

What Is High-Functioning Depression?

High-functioning depression is not a formal clinical diagnosis, but it often overlaps with Persistent Depressive Disorder (PDD) — a chronic, long-term form of depression.

People with this condition may:

     Maintain steady employment

     Show up socially

     Fulfill responsibilities

     Appear “put together”

Yet internally, they experience ongoing sadness, emotional numbness, low energy, or feelings of inadequacy.

Life may look stable on the outside.

Inside, it feels heavy.

Why It Often Goes Unnoticed

Unlike major depressive episodes, high-functioning depression doesn’t always interrupt daily functioning in obvious ways.

In fact, some people cope by over-functioning.

They may:

     Work longer hours

     Overcommit socially

     Strive for perfection

     Avoid slowing down

Because they are still “handling life,” they may believe their pain isn’t serious enough to deserve help.

That belief can delay treatment for years.

And over time, untreated depression often deepens.

Subtle Signs of High-Functioning Depression

The symptoms may not look dramatic — but they are real and persistent.

1. Ongoing Low Mood

A constant undercurrent of sadness, emptiness, or emotional flatness — even when life seems objectively “fine.”

2. Chronic Fatigue

Not just tired — but emotionally drained.

Getting through daily tasks requires far more effort than it appears to others.

3. Loss of Joy

Activities that once felt meaningful now feel dull. You still participate — but without genuine enjoyment.

4. Overachievement as a Coping Mechanism

Success becomes a distraction.

Staying busy prevents emotional reflection — but doesn’t resolve the underlying pain.

5. Harsh Self-Criticism

Even when accomplishing goals, there’s a persistent voice saying:

     “It’s not enough.”

     “You should be doing better.”

     “Anyone else could do this.”

6. Irritability or Emotional Withdrawal

Instead of visible sadness, depression may show up as:

     Short temper

     Emotional distance

     Reduced vulnerability

7. Sleep Changes

Trouble falling asleep. Waking too early. Or sleeping excessively but still feeling exhausted.

8. Physical Symptoms

Headaches, stomach discomfort, muscle tension, or body aches without a clear medical explanation — often connected to chronic stress.

The Hidden Cost of “Holding It Together”

High-functioning depression requires enormous internal energy.

Over time, that emotional strain can lead to:

     Burnout

     Worsening depressive symptoms

     Anxiety

     Emotional numbness

     Suicidal thoughts

According to the World Health Organization, more than 280 million people worldwide live with depression — and many never receive treatment.

Functioning does not mean thriving.

And coping does not mean healing.

Why Many People Don’t Seek Help

There are common barriers:

Stigma

Fear of being seen as weak or dramatic.

Minimizing the Pain

“I’m still working. It can’t be that bad.”

Fear of Disruption

Concerns that therapy or treatment might interfere with responsibilities.

Lack of Awareness

Not recognizing that chronic low mood qualifies as depression.

But depression doesn’t need to become debilitating before it deserves care.

When to Seek Support

Consider reaching out if you notice:

     Persistent sadness lasting more than two weeks

     Loss of interest in activities

     Ongoing fatigue not relieved by rest

     Feelings of hopelessness

     Thoughts of self-harm or suicide

Even “mild” symptoms are valid reasons to seek help.

Early intervention often prevents symptoms from worsening.

How to Get Help

Healing is possible — and support comes in many forms.

1. Therapy

Therapy provides a structured space to unpack emotional weight.

Effective approaches include:

Cognitive Behavioral Therapy (CBT): Helps identify and reframe negative thought patterns.

Interpersonal Therapy (IPT): Focuses on improving relationships and communication.

Therapy is not just for crisis. It’s for clarity and relief.

2. Medication

For some individuals, antidepressants help regulate brain chemistry.

Medication is often most effective when combined with therapy and lifestyle support.

A qualified medical provider can guide this decision.

3. Lifestyle Support

Small, consistent habits can significantly reduce depressive symptoms.

     Exercise: Research shows regular physical activity reduces depression symptoms by 20–30%.

     Nutrition: Balanced meals support brain health and energy regulation.

     Sleep hygiene: Consistent sleep schedules improve emotional regulation.

Lifestyle changes aren’t a cure — but they are powerful tools.

4. Connection and Community

Depression thrives in isolation.

Research published in PLOS Medicine shows strong social relationships increase survival rates by 50% and significantly improve resilience.

Share honestly with someone safe.

You don’t need to explain everything — just start somewhere.

5. Mindfulness and Stress Reduction

Practices like:

     Meditation

     Journaling

     Gentle yoga

     Breathwork

help regulate the nervous system and reduce rumination.

Mindfulness doesn’t erase depression — but it reduces its intensity.

Supporting Someone Who May Be Struggling

If someone in your life seems “fine” but something feels off:

     Check in regularly

     Ask open-ended questions

     Listen without trying to fix

     Avoid minimizing statements like “You’re doing great though!”

     Encourage professional support gently

Small acts — a text, a shared meal, consistent presence — matter more than you think.

Final Thoughts

High-functioning depression is often invisible.

It hides behind productivity. Behind smiles. Behind accomplishments.

But emotional pain does not need to reach a breaking point before it deserves attention.

You don’t have to wait until everything collapses to ask for help.

Reaching out is not a weakness.

  • It is self-awareness.
  • It is courage.
  • It is the beginning of healing.

With the right support, relief is possible — even if you’ve been “holding it together” for a long time.

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Special offers